Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK.

Gynecol Oncol. 2011 Nov;123(2):370-8. doi: 10.1016/j.ygyno.2011.07.002. Epub 2011 Jul 30.

PMID:
21803404
2.

Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK.

PLoS One. 2012;7(4):e34443. doi: 10.1371/journal.pone.0034443. Epub 2012 Apr 3.

3.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.

4.

Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.

Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gerçel-Taylor C.

Gynecol Oncol. 1997 Apr;65(1):13-22.

PMID:
9103385
5.

Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis.

Peng B, Chang Q, Wang L, Hu Q, Wang Y, Tang J, Liu X.

Gynecol Oncol. 2008 Jan;108(1):173-81. Epub 2007 Oct 23.

PMID:
17959232
6.

Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.

Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA.

Oncology. 2006;70(6):483-92. Epub 2007 Jan 18.

PMID:
17237623
7.

The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.

Shany S, Levy Y, Lahav-Cohen M.

Steroids. 2001 Mar-May;66(3-5):319-25.

PMID:
11179740
8.

Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells.

Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK.

Chem Biol Drug Des. 2012 Jan;79(1):92-103. doi: 10.1111/j.1747-0285.2011.01251.x. Epub 2011 Nov 4.

PMID:
21974809
9.

Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.

Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W.

Clin Cancer Res. 2005 Jan 1;11(1):323-8.

10.

Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines.

Huh SW, Bae SM, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim SH, Kim CK, Ahn WS.

Gynecol Oncol. 2004 Sep;94(3):760-8.

PMID:
15350370
12.

Vitamin D receptor is a novel drug target for ovarian cancer treatment.

Zhang X, Nicosia SV, Bai W.

Curr Cancer Drug Targets. 2006 May;6(3):229-44. Review.

PMID:
16712459
13.

Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.

Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C.

Invest New Drugs. 2005 Jun;23(3):205-11.

PMID:
15868376
15.
16.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
17.

Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.

Kumagai T, O'Kelly J, Said JW, Koeffler HP.

J Natl Cancer Inst. 2003 Jun 18;95(12):896-905.

PMID:
12813173
18.
19.

Cytotoxicity of natural extract from Tegillarca granosa on ovarian cancer cells is mediated by multiple molecules.

Gao MQ, Han YT, Zhu L, Chen SG, Hong ZY, Wang CB.

Clin Invest Med. 2009 Oct 1;32(5):E368-75.

PMID:
19796578
20.

Antitumor effect of GnRH agonist in epithelial ovarian cancer.

Kim JH, Park DC, Kim JW, Choi YK, Lew YO, Kim DH, Jung JK, Lim YA, Namkoong SE.

Gynecol Oncol. 1999 Aug;74(2):170-80.

PMID:
10419728

Supplemental Content

Support Center